Search clinical trials for: RT001

Total 42 results

Revance Therapeutics, Inc.

Completed

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

Facial Wrinkles | Lateral Canthal Lines | Crow's Feet

United States
Shanghai Vinnerna Biosciences Co., Ltd.

Withdrawn

Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets

Healthy Subjects

Australia
Revance Therapeutics, Inc.

Completed

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

Lateral Canthal Lines

United States
Pearl Therapeutics, Inc.

Completed

Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects

Healthy Volunteers

Australia
Revance Therapeutics, Inc.

Completed

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

Facial Wrinkles | Lateral Canthal Lines | Crow's Feet

United States
Retrotope, Inc.

Completed

A First in Human Study of RT001 in Patients With Friedreich's Ataxia

Friedreich's Ataxia

United States
Shanghai Vinnerna Biosciences Co., Ltd.

Recruiting

A Real-World Study of JT001 for COVID-19

COVID-19

China
Retrotope, Inc.

Completed

A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia

Friedreich's Ataxia

United States
Shanghai JunTop Biosciences Co., LTD
Sponsor GmbH

Terminated

JT001 (VV116) for the Early Treatment of COVID-19

Mild to Moderate COVID-19

China, Hong Kong
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Recruiting

The Mass Balance Study of [14C]JT001

Healthy Subjects

China
Retrotope, Inc.

Active, not recruiting

A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy

Infantile Neuroaxonal Dystrophy

United States
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

JT001 (VV116) for the Treatment of COVID-19

Mild to Moderate COVID-19

China
Pearl Therapeutics, Inc.

Completed

PT003 MDI Dose Confirmation Study

Chronic Obstructive Pulmonary Disease

United States
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

A Study in Elderly Chinese Subjects With Underlying Diseases

Elderly Subjects With Underlying Diseases

China
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Terminated

Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

Moderate to Severe COVID-19

China, Uzbekistan
Regor Pharmaceuticals Inc.

Recruiting

A Study of RGT001-075 in Adult Patients With Obesity

Obesity

United States
Retrotope, Inc.

Recruiting

RT001 in Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

Netherlands, Estonia, Latvia, Sweden
Regor Pharmaceuticals Inc.

Terminated

A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
Retrotope, Inc.

Recruiting

RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY

Progressive Supranuclear Palsy

Germany
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function

Subjects With Liver Function Injury | Normal Liver Function Subject

China
Cessatech A/S

Not yet recruiting

Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients

Pain
Cessatech A/S

Completed

Pharmacokinetic Study of Intranasal CT001 in Children 1-17 Years of Age Undergoing Elective Surgical Procedures

Analgesia

Denmark
Revance Therapeutics, Inc.

Completed

A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

Facial Wrinkles | Lateral Canthal Lines | Crow's Feet

United States
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD

COPD, Chronic Obstructive Pulmonary Disease

Belgium
Pearl Therapeutics, Inc.

Completed

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease

United States
Santen Inc.
MacuSight, Inc.

Completed

Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Diabetic Retinopathy | Diabetic Macular Edema

United States
Revance Therapeutics, Inc.

Completed

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

Lateral Canthal Lines

United States
Santen Inc.
MacuSight, Inc.

Terminated

Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration

Age-related Macular Degeneration | Choroidal Neovascularization

United States
Santen Inc.
MacuSight, Inc.

Completed

Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema

Diabetic Macular Edema

United States
Santen Inc.
MacuSight, Inc.

Completed

A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model

Dry Eye

United States
Vigonvita Life Sciences

Completed

Efficacy and Safety of JT001 (VV116) Compared With Paxlovid

COVID-19

China
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

Chronic Obstructive Pulmonary Disease

United States, Germany, United Kingdom, China, Taiwan, Korea, Republic of, Japan, Czechia, Hungary, Poland, Russian Federation
Cessatech A/S

Completed

Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001

Pain

Denmark
Cessatech A/S
Smerud Medical Research International AS; Dantrials Aps

Completed

Study of CT001 in Healthy Volunteers

Bioavailability

Denmark
Pearl Therapeutics, Inc.

Completed

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, New Zealand
Santen Inc.
MacuSight, Inc.

Terminated

Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration (EMERALD)

Age-Related Macular Degeneration | Choroidal Neovascularization

United States
Pearl Therapeutics, Inc.

Completed

PT003 MDI Cardiovascular Safety Study

Chronic Obstructive Pulmonary Disease

United States, Australia, New Zealand
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Australia, United States, New Zealand
Pearl Therapeutics, Inc.

Completed

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Chronic Obstructive Pulmonary Disease (COPD)

United States

Search clinical trials for: RT001

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations